Showing 1 - 10 of 1,008
We perform an econometric investigation of the contribution of pharmaceutical innovation to mortality reduction and … pharmaceutical innovation, there would have been no increase and perhaps even a small decrease in mean age at death, and that new … drugs have increased life expectancy, and lifetime income, by about 0.75-1.0% per annum. The drug innovation measures are …
Persistent link: https://www.econbiz.de/10012472240
of decline across cancer sites. I analyze the effect that pharmaceutical innovation had on premature cancer mortality in … Canada during the period 2000-2011, by investigating whether the cancer sites that experienced more pharmaceutical innovation …The estimates imply that pharmaceutical innovation during the period 1985-1996 reduced the number of years of potential …
Persistent link: https://www.econbiz.de/10012457428
This paper introduces a newly digitized, open-access version of the Food and Drug Administration's "Orange Book"--a linkage between approved small-molecule drugs and the patents that protect them. The Orange Book also reports any applicable regulatory exclusivity that prevents competitive entry....
Persistent link: https://www.econbiz.de/10013462677
This study investigates how enhanced regulation can promote innovation, focusing on the impacts of a significant … recognized the improvement in drug innovation, as reflected in stock price adjustments post new drug registrations after the … latecomers could boost their innovation potential by adopting specific, effective regulatory practices from frontier countries …
Persistent link: https://www.econbiz.de/10014447297
Rewarding inventors with inefficient monopoly power has long been regarded as the price of encouraging innovation …, while simultaneously encouraging dynamic investments in innovation. As a result of this feature, the public provision of … at least $2.8 billion of annual value from extra innovation. These two components alone cover 87% of the social cost of …
Persistent link: https://www.econbiz.de/10012465145
This paper compares the clinical trial strategies and performance of large, established ("mature") biopharmaceutical firms to those of smaller ("early stage") firms that have not yet successfully developed a drug. We study a sample of 235 cancer drug candidates that entered clinical trials...
Persistent link: https://www.econbiz.de/10012467754
This paper examines trends in the aggregate productivity of the pharmaceutical sector over the past three decades. We incorporate Ricardo's insight about demand-driven productivity in settings of variable scarce resources, and estimate the industry's responsiveness to changes in demand over this...
Persistent link: https://www.econbiz.de/10012455960
In 1996, following an epidemic, Pfizer tested a new drug on 200 children in Muslim Nigeria. 11 children died while others were disabled. We study the effects of the disclosure, in 2000, of the deaths of Muslim children in the Pfizer trials on vaccine compliance among Muslim mothers. Muslim...
Persistent link: https://www.econbiz.de/10014372412
We examine the role of spillover learning in shaping the value of exploratory versus incremental R&D. Using data from drug development, we show that novel drug candidates generate more knowledge spillovers than incremental ones. Despite being less likely to reach regulatory approval, they are...
Persistent link: https://www.econbiz.de/10014287391
Prior literature has established a link between changes in market size and pharmaceutical innovation; whether a link … conducting applied research. Implications for pharmaceutical innovation policy are discussed …
Persistent link: https://www.econbiz.de/10012533407